3种治疗高血压药物的药物经济学分析及患者依从性的评估

董松飞; 宁微微; 徐昕; 易斌; 叶金飞

引用本文:	董松飞,宁微微,徐昕,易斌,叶金飞.3种治疗高血压药物的药物经济学分析及患者依从性的评估[J].中国现代应用药学,2013,30(7):792-795.
	DONG Songfei,NING Weiwei,XÜ Xin,YI Bin,YE Jinfei.Cost-effectiveness Analysis of Three Drugs in Treatment of Hypertension and Assessment of Patients’ Compliance[J].Chin J Mod Appl Pharm(中国现代应用药学),2013,30(7):792-795.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 2578次下载 2206次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
3种治疗高血压药物的药物经济学分析及患者依从性的评估
董松飞¹, 宁微微¹, 徐昕¹, 易斌¹, 叶金飞²
1.象山县第一人民医院，浙江象山 315700;2.象山县中医院浙江象山 315700

摘要:

目的评价苯磺酸氨氯地平、厄贝沙坦和非洛地平3种治疗轻中度原发性高血压的临床疗效和费用，评估患者的依从性。方法 150例原发性高血压患者随机分成A、B、C组，分别给予A组：苯磺酸氨氯地平2.5 mg·d^-1，B组：厄贝沙坦片150 mg·d^-1，C组：非洛地平缓释片5 mg·d^-1。治疗过程中用问卷调查及随访表形式，调查患者依从性情况。治疗8周，观察临床疗效，运用药物经济学的成本-效果分析方法进行评价。结果 3种方案有效率分别为78.0％，80.0％，84.0％；成本分别为59.36，147.84，222.32元。通过调查与随访，A组患者依从性最佳。结论高血压病的医院治疗应科学选用治疗药物，为患者制定经济、合理、安全、有效的治疗方案。综合考虑，在同等疗效基础上苯磺酸氨氯地平更有经济性优势。

关键词: 高血压成本-效果分析药物经济学依从性

DOI：

分类号:

基金项目:

Cost-effectiveness Analysis of Three Drugs in Treatment of Hypertension and Assessment of Patients’ Compliance

DONG Songfei¹, NING Weiwei¹, XÜ Xin¹, YI Bin¹, YE Jinfei²

1.The First People’s Hospital of Xiangshan, Xiangshan 315700, China;2.The Traditional Chinese Medicine Hospital of Xiangshan, Xiangshan 315700, China

Abstract:

OBJECTIVE To compare the curative effects and pharmaceconomical efficacy of 3 drugs in the treatment of mild or moderate essential hypertension. METHODS A total of 150 cases of hypertension patients were randomly divided into 3 groups, group A (amlodipine besylate, 2.5 mg·d^-1), group B (irbesartan, 150 mg·d^-1), group C (felodipine sustained release, 5 mg·d^-1). During the treatment, patients’ compliance with questions and follow-up survey were investigate. The curative effects in each group were observed, and the cost-effectiveness ratios were analyzed after 8-week treatment. RESULTS The total effective rates of the 3 groups(A, B, and C) were 78.0%, 80.0% and 84.0%, respectively. The cost-effectiveness ratios were 59.36, 147.84 and 222.32 yuan, respectively. The best compliance was observed in group A. CONCLUSION Antihypertention therapy should be economic, reasonable, safe and effective. Amlodipine besylate treatment is more reasonable.

Key words: hypertension cost-effectiveness analysis pharmacoeconmics compliance